This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Xencor (XNCR) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Xencor (XNCR) delivered earnings and revenue surprises of -8.93% and 43.47%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Xencor (XNCR) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Xencor (XNCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Incyte, MorphoSys Application for Lymphoma Drug Validated
by Zacks Equity Research
Incyte (INCY) and partner MorphoSys' application for tafasitamab gets validation by EMA.
MorphoSys BLA for Cancer Drug Gets Priority Review from FDA
by Zacks Equity Research
MorphoSys (MOR) BLA for blood cancer drug gets Priority Review from the FDA.
Xencor (XNCR) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Xencor (XNCR) delivered earnings and revenue surprises of 9.62% and -47.76%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Bausch's (BHC) Q4 Earnings Match Estimates, Revenues Miss
by Zacks Equity Research
Bausch (BHC) reports mixed fourth-quarter results, with earnings meeting expectations but sales missing the same.
Gilead (GILD) Inks License Deal with Xencor for HIV Candidate
by Zacks Equity Research
Gilead Sciences (GILD) entered into a technology license agreement with Xencor for use of XmAb antibody technologies in investigational agents for HIV.
Company News For Dec 30, 2019
by Zacks Equity Research
Companies in the news are: MIK, XNCR, PT, FCEL
Xencor (XNCR) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Xencor (XNCR) delivered earnings and revenue surprises of 68.97% and 371.51%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Xencor (XNCR) Q3 Earnings Expected to Decline
by Zacks Equity Research
Xencor (XNCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Xencor (XNCR) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Xencor (XNCR) delivered earnings and revenue surprises of 33.33% and 156.99%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Xencor (XNCR) Jumps: Stock Rises 7.4%
by Zacks Equity Research
Xencor (XNCR) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Company News For Jun 26, 2019
by Zacks Equity Research
Companies in the news are: ABBV, AGN, LEN, XNCR, USNA and LION
Xencor (XNCR) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Xencor (XNCR) delivered earnings and revenue surprises of 220.93% and 86.41%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Nielsen (NLSN) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Partnerships and agreements are likely to drive Nielsen's (NLSN) fourth-quarter 2018 revenues. However, weakness in the Buy segment and increasing competition may impact its profits.
What's in Store for Booking Holdings' (BKNG) Q4 Earnings?
by Zacks Equity Research
Booking Holdings' (BKNG) Q4 earnings are likely to reflect growth in international markets.
Earnings Preview: Xencor (XNCR) Q3 Earnings Expected to Decline
by Zacks Equity Research
Xencor (XNCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Xencor Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Xencor Sees Hammer Chart Pattern: Time to Buy?
Xencor (XNCR) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Xencor (XNCR) delivered earnings and revenue surprises of 16.36% and -100.00%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Novartis (NVS) In-Licenses Ophthalmic Drug from Lubris LLC
by Zacks Equity Research
Novartis AG (NVS) recently announced that it has exercised an option to in-license ECF843 for ophthalmic indications worldwide from Lubris LLC.
Novartis' Tafinlar, Mekinist Get EU Approval for NSCLC
by Zacks Equity Research
Novartis AG (NVS) recently announced that the European Commission has approved Tafinlar in combination with Mekinist for the treatment of patients with BRAF V600-positive advanced or metastatic non-small cell lung cancer (NSCLC).
Increased Earnings Estimates Seen for Xencor (XNCR): Can It Move Higher?
by Zacks Equity Research
Xencor (XNCR) could be good choice for investors as it is seeing decent short-term momentum and positive earnings estimate revisions.
Novartis' Acute Heart Failure Drug Fails in Late-Stage Study
by Zacks Equity Research
Novartis AG (NVS) recently suffered a setback on the announcement of disappointing data from a phase III study, RELAX-AHF-2, on pipeline candidate serelaxin (RLX030).
Novartis (NVS) Announces Positive Data on Heart Failure Drug
by Zacks Equity Research
Novartis AG (NVS) recently announced results of a new post-hoc analysis from the PARADIGM-HF study on heart failure drug Entresto.
Novartis Breast Cancer Drug OK'd by FDA as First-line Therapy
by Zacks Equity Research
Novartis AG (NVS) announced that the FDA has approved Kisqali, for use in combination with an aromatase inhibitor for the first-line treatment of postmenopausal women with hormone receptor positive, HR+/HER2- advanced or metastatic breast cancer.